Pipeline
We are developing two primary compounds, NVC-101 (also referred to as NeutroPhase™) and NVC-422, which we intend to use in the development of products to treat various bacterial infections. NVC-422 is our lead compound in a new class of antimicrobial compounds that we call the Aganocide® compounds.
